Results 101 to 110 of about 48,983 (212)

Cutaneous reactions during treatment with Nifurtimox or Benznidazole among Trypanosoma cruzi seropositive adults without symptomatic cardiomyopathy: A safety sub analysis of a placebo‐controlled randomised trial

Tropical Medicine &International Health, EarlyView.
Abstract Objectives To determine, in a randomised placebo‐controlled trial, if cutaneous adverse reactions during treatment (CARDT) with Benznidazole occur as often as with Nifurtimox, and whether the dose and duration of treatment change that frequency.
Juan Carlos Villar, María Fernanda Saavedra, Pablo Andrés Bermúdez, Eliana Váquiro Herrera, Skarlet Marcell Vásquez, Helena Arango, Antonia Camacho, Mario Javier Olivera   +7 more
wiley   +1 more source

Unhealthy Behaviours and All‐Cause Mortality Among People With Chronic Hepatitis B, With and Without Hepatitis Delta (ANRS CO22 HEPATHER)

Journal of Viral Hepatitis, Volume 32, Issue 7, July 2025.
ABSTRACT People infected with both hepatitis B virus (HBV) and hepatitis Delta virus (HDV) face a higher mortality risk than those mono‐infected with HBV. As unhealthy behaviours can influence liver disease progression, we compared the effects of various behavioural factors on all‐cause mortality among people with chronic hepatitis B (CHB), with or ...
Clémence Ramier, Fabrice Carrat, Vincent Di Beo, Lucia Parlati, Marta Lotto, Fabienne Marcellin, Camelia Protopopescu, Patrizia Carrieri, Marc Bourliere, the ANRS/AFEF HEPATHER study group   +9 more
wiley   +1 more source

NCATS Proposal – ALS Patients Demand [PDF]

, 2020
Barohn, Richard J., Statland, Jeffrey M.
core   +2 more sources

Clinical evaluation and outcome in heart failure patients receiving chemotherapy with different anti‐cancer agents

ESC Heart Failure, Volume 12, Issue 3, Page 1965-1976, June 2025.
Abstract Background The optimal strategy for modern chemotherapy should be based on a comprehensive approach for cancer patients with cardiovascular diseases. Therefore, cardio‐oncology has received increasing attention owing to the cardiotoxic effects of anti‐cancer therapies.
Tomiko Sunaga, Takahiro Okada, Yoshitaka Iso, Mio Ebato, Tsutomu Toshida, Shuichi Nawata, Hiroshi Suzuki, Mari Kogo   +7 more
wiley   +1 more source

Developing a co-produced e-learning programme to support marginalised medically underserved patients [PDF]

, 2019
Gulzar, Nargis, Latif, Asam, Mandane, Baguiasri   +2 more
core   +1 more source

Pharmacovigilance

Journal of the Royal College of Physicians of London, 1992
openaire   +2 more sources

Linking preclinical models to clinical realities: VEGF/VEGFR inhibitors and thrombotic microangiopathy in cancer therapy

iMetaOmics, Volume 2, Issue 2, June 2025.
This study investigates the risk of thrombotic microangiopathy (TMA) induced by vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) inhibitors in cancer therapy. Using data from the FDA Adverse Event Reporting System (FAERS), the WHO Global Database for Adverse Drug Reactions (Vigibase), and The Cancer ...
Aimin Jiang, Zhanzhi Li, Ying Liu, Junyi Shen, Quan Cheng, Anqi Lin, Peng Luo, Linhui Wang   +7 more
wiley   +1 more source

Changes in the Nationwide Incidence of Bell's Palsy in the General Population Before and After the COVID‐19 Pandemic: An Ecological Study

Journal of Medical Virology, Volume 97, Issue 6, June 2025.
ABSTRACT This nationwide population‐based ecological study investigated changes in the incidence of Bell's palsy (BP) in South Korea during the COVID‐19 pandemic. Patients diagnosed with BP between January 2017 and December 2022 were analyzed. Considering the unique progression of the COVID‐19 pandemic and corresponding public health responses in South
Seungyeon Lee, Nang Kyeong Lee, Seung Won Lee, Yong Joon Kim   +3 more
wiley   +1 more source

Serious Neurologic Adverse Events in Tofersen Clinical Trials for Amyotrophic Lateral Sclerosis

Muscle &Nerve, Volume 71, Issue 6, Page 1006-1015, June 2025.
ABSTRACT Introduction/Aims Tofersen is approved for the treatment of amyotrophic lateral sclerosis (ALS) due to superoxide dismutase 1 mutations (SOD1‐ALS). Here we report serious neurologic adverse events (AEs) that occurred in the tofersen clinical trials in people with SOD1‐ALS.
Alexandra Lovett, Sowmya Chary, Suma Babu, Gaëlle Bruneteau, Jonathan D. Glass, Merete Karlsborg, Shafeeq Ladha, Keith Mayl, Christopher McDermott, Robert C. Bucelli, Adriano Chiò, Toby A. Ferguson, Thos Cochrane, Stephanie Fradette, Karen Smirnakis, Jennifer Inra, Sohail Malek, Laura Fanning   +17 more
wiley   +1 more source

Risk Management of Medication Errors: Improving the Quality of Pharmacotherapeutic Practice

Pharmacology Research &Perspectives, Volume 13, Issue 3, June 2025.
ABSTRACT A key challenge when identifying opportunities and prioritizing strategies for quality improvement of healthcare services is an accurate design specification against which clinical performance can be assessed. This study aimed to explore evidence‐based methods as a more effective framework for quality improvement in pharmacotherapeutic ...
Richard Anthony Despott, Patricia Vella Bonanno, Charmaine Gauci   +2 more
wiley   +1 more source